Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zhaoke Ophthalmology Ltd. anticipates a significant reduction in its loss for the first half of 2024, expecting it to not exceed RMB 77 million, compared to the RMB 233.7 million loss in the same period of 2023. The improvement is attributed to a milestone payment received, lower R&D expenses as major clinical trials near completion, and increased sales of ophthalmic drugs. The company advises caution as these are preliminary results and the final report is due in late August 2024.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.